FDA’s EMDAC recommends approval of Sanofi and Regeneron’s alirocumab
EMDAC voted 13 to 3 that the companies had sufficiently established that the low-density lipoprotein cholesterol (LDL-C) lowering benefit of Praluent exceeds its risks to support approval in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.